Johnson & Johnson (J&J) has reported a 9.1% increase in sales for Q4 2025, reaching $24.56bn, with net earnings rising by 49.1% to $5.11bn.
For the entire year, sales grew by 6% to $94.2bn, and full-year earnings per share (EPS) registered at $11.03.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The diluted earnings per share (EPS) for Q4 2025 stood at $2.10, up from $1.41 in Q4 2024, reflecting a 48.9% growth.
Additionally, the adjusted net earnings were reported at $6.1bn, up by 21.5% from $4.94bn in the same period of the prior year. Adjusted diluted EPS increased to $2.46 from the previous year’s $2.04, translating to a 20.6% growth.
Throughout the year, significant innovations included approvals for Caplyta in treating major depressive disorder and Rybrevant Faspro plus Lazcluze for non-small cell lung cancer.
J&J also announced its guidance for 2026, forecasting estimated reported sales of $100.5bn and an adjusted EPS of $11.53 at the midpoint.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOperational sales of the global innovative medicine sector increased 5.3%, bolstered by products such as Erleada, Darzalex, Carvykti in oncology, and Tremfya in immunology, among others.
Medtech also saw a worldwide operational sales increase of 5.4%, driven mainly by electrophysiology products and Abiomed in cardiovascular and wound closure products in general surgery.
J&J chairman and CEO Joaquin Duato said: “2025 was a catapult year for Johnson & Johnson, fuelled by the strongest portfolio and pipeline in our history.
“Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: oncology, immunology, neuroscience, cardiovascular, surgery, and vision. In each of these important areas, our leadership is expanding, driven by game-changing science and technology.”
In December 2025, J&J completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05bn in cash.
